A Heart Disease Drug for Cancer
Posted: under Biology, Biotech, Chemistry, Medicine.
Chemotherapy sucks. While it can buy the sick time and even produce cures, patients must endure hair loss, nausea and vomiting, weakened immune systems, nerve damage, and even the risk of secondary cancers, cancers that are caused by the very same drugs designed to treat them. And perhaps most tragically, chemotherapy often fails to cure a patient’s illness, as neoplasias often evolve to both become resistant to treatment and to spread, or metastasize, all over the body. However, there may be a non-chemo based drug, that’s already approved by the FDA and on the market, which can reduce the chance that a cancer will metastasize and develop resistance to chemotherapy. This drug is called digoxin.
Digoxin, which is derived from the flowering plant known as fox glove, is currently approved as a treatment for a variety of heart problems. And although digoxin, because it is not without side effects and risks of its own, is no longer the first choice for patients with heart problems, it remains a safe and effective drug when given at appropriate doses. So how could a drug used for heart problems be used to treat cancer? The answer lies in a condition known as hypoxia, which is oxygen deprivation within a tumor. Research has indicated that hypoxia both increases the chances that cancer cells will be resistant to chemotherapy and metastasize. Digoxin may benefit cancer treatment because it may be able to reduce hypoxia, and thus reduce chemotherapy resistance and metastasis.
How does digoxin reduce hypoxia? At the molecular level, the response of cancer cells to hypoxia is still not completely understood, but scientists do know that hypoxia causes hundreds of genes to become activated. However, many of these genes only become activated because of a transcription factor called HIF-1 a, or “hypoxia inducible factor 1 alpha”. HIF-1-a is one of the first proteins that a cancerous cell makes in response to hypoxia, and because it activates hundreds of other genes it can be viewed as a master regulator of a cancer cell’s response to hypoxia: expose cancer cells to hypoxia and they make HIF-1a, HIF-1a then turns on lots of other genes that make a cancer cell more likely to be chemoresistant and metastatic. Digoxin works because it has been shown to inhibit HIF-1a; turn off the master regulator and you inhibit the hypoxic response.
There are already clinical trials testing the use of digoxin as an adjuvant to chemotherapy and radiation. The hope is that digoxin will be able to prevent metastasis and sensitize cancer cells to treatment. I can’t wait to see the results.
Sources:
http://breast-cancer-research.com/content/10/6/R102
http://www.modernmedicine.com/modernmedicine/Nursing/ArticleNewsFeed/article/detail/574333
http://clinicaltrials.gov/ct2/show/NCT00281021
http://www.ncbi.nlm.nih.gov/pubmed/20671264
http://www.ncbi.nlm.nih.gov/pubmed/19938317
http://en.wikipedia.org/wiki/Digoxin#Clinical_use
Comments (0)
Aug 27 2010